SCHEMBL367502

SCHEMBL367502

NC(=O)c1cccc(C(=O)N2CCCC2)c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.65
L3MBTL3 Q96JM7 3/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.58
LMNA P02545 2/20 0.58
POLB P06746 1/20 0.58
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 5/20 0.56
GAA P10253 3/20 0.56
MEN1 O00255 1/20 0.56
HTT P42858 1/20 0.56
KMT2A Q03164 1/20 0.56
TP53 P04637 1/20 0.54
USP2 O75604 2/20 0.54
MAPT P10636 1/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
RXFP1 Q9HBX9 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL472245 0.98 HPGD (0.66) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA
SCHEMBL28377650 0.98 HPGD (0.66) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA
SCHEMBL367274 0.98 HPGD (0.66) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA
SCHEMBL538527 0.98 HPGD (0.66) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA
SCHEMBL472260 0.98 HPGD (0.66) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA
SCHEMBL6902996 0.98 HPGD (0.66) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA
SCHEMBL538600 0.98 HPGD (0.66) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA
SCHEMBL369227 0.98 HPGD (0.66) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA
SCHEMBL180076 0.98 HPGD (0.66) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA
Terephthalamide SCHEMBL198417 0.95 HPGD (0.62) HPGDL3MBTL3L3MBTL1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 US claimed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 US claimed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 US claimed
EP-1819341-A2 IL-12 MODULATORY COMPOUNDS Synta Pharmaceuticals Corporation (US) 2007-08-22 EP claimed
US-20060223996-A1 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-10-05 US claimed
WO-2006053227-A2 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 WO claimed
EP-0411709-B1 Polyamide composition DSM NV (NL) 1994-06-01 EP claimed
EP-0270146-B1 COPOLYAMIDE AND A PROCESS FOR THE PREPARATION THEREOF DSM N.V. (NL) 1992-09-23 EP claimed
US-5084552-A Tetramethylenediamine with adipic acid, terephthalic acid and isophthalic acid terpolyamide for moldings and films STAMICARBON B.V. (NL) 1992-01-28 US claimed
EP-0411709-A1 Polyamide composition DSM N.V. (NL) 1991-02-06 EP claimed
EP-0270146-A1 Copolyamide and a process for the preparation thereof DSM N.V. (NL) 1988-06-08 EP claimed
EP-0247203-A1 POLYAMIDE PACKAGING MATERIAL TEIJIN LIMITED (JP) 1987-12-02 EP claimed
WO-1987002680-A2 POLYAMIDE PACKAGING MATERIAL TEIJIN LIMITED (JP) 1987-05-07 WO claimed
JP-62106926-A None JP disclosed
CN-112226081-B Laser sensitization resin composition, preparation method and application thereof 中国石油化工股份有限公司 2023-05-02 CN disclosed
US-11254082-B2 Multi-layer tube UBE INDUSTRIES, LTD. (JP) 2022-02-22 US disclosed
JP-S62106926-A POLYAMIDE PACKAGING MATERIAL TEIJIN LTD 1987-05-18 JP disclosed
WO-1987002680-A2 POLYAMIDE PACKAGING MATERIAL TEIJIN LIMITED (JP) 1987-05-07 WO disclosed
WO-1987002680-A2 POLYAMIDE PACKAGING MATERIAL TEIJIN LIMITED (JP) 1987-05-07 WO disclosed
EP-0219973-A2 Impact resistant polyamide compositions Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1987-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223996-A1 IL-12 modulatory compounds IL2, IL4, IFNG HPGD 146/4885L3MBTL3 4667/4885L3MBTL1 4697/4885
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG HPGD 146/4885L3MBTL3 4667/4885L3MBTL1 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.